Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
Panna SharmaPresident, CEO & Director Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar....
I’m Bullish On RF Industries With Eyes Wide Open (NASDAQ:RFIL)
NTSI: Leveraged Balanced International Equity Treasury ETF, Strong Strategy, Thesis (NTSI)
Heartland Express Has Secularly Declining Returns On Capital (NASDAQ:HTLD)
Silver: My 2017 Thesis On Industrial Demand, Why This Is Not A Silver Market Bubble
FEPI ETF: This 25% Yielder Is About To Generate Even Bigger Income (NASDAQ:FEPI)